Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT NXT: Efgartigimod IV in Generalized Myasthenia Gravis
NCT04980495Phase 3Completed
- Sponsor
- argenx
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Antibody Fragments
- Countries
- 11
01
Overview
A Phase 3 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Started Dec 2021; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04980495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980495.